GUT MICROBIOME 2018

GUT MICROBIOME

PROGRAM Information

Release Date: July, 2018
Expiration Date: July, 2019

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with common gastrointestinal (GI) disorders such as IBS and small intestinal bacterial overgrowth (SIBO).

Educational Objectives

After completing this program, participants should be better able to:

Discuss evolving concepts regarding the role of the gut microbiome in gastrointestinal health and disease

Describe current research advances in understanding the composition and function of the gut microbiome

Discuss how modification of the gut microbiome can be used as a therapeutic strategy in gastrointestinal diseases


Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Gi Health Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accredited by

Provided by Gi Health Foundation

This program is not affiliated with Digestive Disease Week®.
Supported by an educational grant from Salix Pharmaceuticals, Inc., A Division of Valeant Pharmaceuticals North America LLC

For more information, email us at info@GiHealthFoundation.org, or call 1-877-782-4532.

(SELECT A SPEAKER TO VIEW THEIR BIO AND DISCLOSURE)

Mark Pimentel, MD, FRCP(C)
(CHAIR)

Cedars-Sinai Medical Center
Los Angeles, California

Janelle C. Arthur, PhD

University of North Carolina
at Chapel Hill
Chapel Hill, North Carolina

Mark S. Riddle, MD, DrPH

Walter Reed National Military
Medical Center
Bethesda, Maryland

Gary D. Wu, MD

University of Pennsylvania
Philadelphia, Pennsylvania

Agenda

Introduction Mark Pimentel, MD

Understanding the Link Between the
Microbiome and Health and Disease Gary D. Wu, MD

The Microbiome and IBS Mark Pimentel, MD

The Microbiome and Infection:
When Good Bugs Meet Bad Bugs Mark S. Riddle, MD

The Microbiome and Cancer Janelle C. Arthur, PhD

Recognition Field Report/Panel Discussion/
Extended Q&A

Mark Pimentel, MD, FRCP(C)
Executive Director, Medically Associated Science and
Technology (MAST) Program
Professor of Medicine, Geffen School of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Mark Pimentel, MD, FRCP(C) is professor of medicine, Geffen School of Medicine and associate professor at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Pimentel completed a three-year undergraduate degree with honors in microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree and his BSc (Med) from the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada, where he also completed a residency in internal medicine. His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program. Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational, and clinical studies in areas such as IBS and the relationship between gut flora composition and human disease. His work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others. Dr. Pimentel has been invited to present his work at meetings, grand rounds, and advisory boards in the United States and internationally. He is diplomate of the American Board of Internal Medicine (Gastroenterology) and a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Pimentel is also a member of several medical associations including the American Gastroenterological Association, the American College of Gastroenterology, and the American Neurogastroenterology and Motility Society.
A few of Dr. Pimentel's most significant accomplishments include:
1. Discovered rifaximin as a treatment for irritable bowel syndrome (IBS)
2. Developed the first blood test for IBS on the basis of IBS being derived from acute gastroenteritis
3. Described the association between IBS and bacterial overgrowth, which forms the basis for microbiome therapies in this condition
4. Uncovered methanogen (M. smithii) as an agent for causing constipation in humans.
5. Discovered the use of lovastatin as a microbiome treatment for constipation on the basis of inhibiting methane production by methanogens

SPEAKER DISCLOSURES

Grants/Research Support:  Valeant Pharmaceuticals

Consultant/Speakers' Bureau/Editorial Board Involvement:  Hobbs Medical, Naia Pharmaceuticals, Shire, Synthetic Biologics, Inc., and Valeant Pharmaceuticals

Advisory Board Membership:  Naia Pharmaceuticals, Shire, Synthetic Biologics, Inc., and Valeant Pharmaceuticals

Stockholder:  Synthetic Biologics, Inc., and Naia Pharmaceuticals

Honorarium Recipient:  Naia Pharmaceuticals, Synthetic Biologics, Inc., and Valeant Pharmaceuticals

Editorial Board Involvement:  American Journal of Gastroenterology

Other Financial Material Support:  Cedars-Sinai has licensing agreements with Commonwealth Diagnostics International, Hobbs Medical, Naia Pharmaceuticals, Synthetic Biologics, Inc., and Valeant Pharmaceuticals

Janelle C. Arthur, PhD
Assistant Professor
Department of Microbiology & Immunology
Lineberger Comprehensive Cancer Center
Center for Gastrointestinal Biology and Disease
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Janelle C. Arthur, PhD, is an assistant professor in the Department of Microbiology & Immunology at the University of North Carolina (UNC) at Chapel Hill. A native of the Boston area, Dr. Arthur received her undergraduate degree in Biotechnology at Worcester Polytechnic Institute in Massachusetts. She then moved to North Carolina to pursue her PhD in Immunology and Microbiology at UNC with Dr. Jenny Ting. Supported by an NIH NIAID T32 pre-doctoral fellowship, Dr. Arthur identified an important role for a newly discovered intracellular innate immunity protein, NLRP12, in controlling immune cell migration. During her transition to postdoctoral research, Dr. Arthur joined the Department of Medicine under the direction of Dr. Christian Jobin, where she was funded by a postdoctoral NIH NIDDK T32 fellowship and an American Cancer Society fellowship. Here she became fascinated with the newly appreciated gut microbiota and its role in intestinal inflammation and colorectal cancer. This field was in its infancy, ripe with unanswered questions, and had the potential to become a novel therapeutic target for both systemic and digestive diseases. Dr. Arthur’s research revealed that chronic intestinal inflammation induces an expansion of resident bacteria with specific cancer-promoting activities. Dr. Arthur further developed her independent research with mentoring from Dr. R. Balfour Sartor and joined the UNC Microbiology & Immunology department as faculty in 2015.

In the microbiome field, the association of microbial dysbiosis with intestinal inflammation is generally accepted but the functional consequences of this altered microbial community on the development of inflammation-associated co-morbidities, such as fibrosis and colorectal cancer, are essentially unknown. Dr. Arthur's research has contributed to a greater understanding of mechanisms by which resident intestinal microbes can influence inflammation, fibrosis, and neoplasia. This work has been published in Science, Nature Communications, and Immunity, among others. Dr. Arthur has been awarded funding from the NIH NIDDK, the Rainin Foundation, the American Gastroenterological Association, the North Carolina Translational and Clinical Sciences Institute, the UNC Center for Gastrointestinal Biology and Disease, and the UNC Lineberger Comprehensive Cancer Center. Currently, Dr. Arthur continues to evaluate the relationship between the gut microbiota, intestinal inflammation, and inflammation-associated co-morbidities with the ultimate goal of identifying novel microbial targets for the diagnosis, prevention, and treatment of digestive diseases.

SPEAKER DISCLOSURES

No relationships to disclose

Mark S. Riddle, MD, DrPH, MPH&TM
International Travel Medicine Clinic
Walter Reed National Military Medical Center
Bethesda, Maryland

Mark S. Riddle, MD, DrPH, MPH&TM, is professor of preventive medicine and biostatistics at the Uniformed Services University in Bethesda, Maryland. Dr. Riddle completed his undergraduate degrees in human development and zoology at the University of California at Davis. This was followed by a medical degree and a Masters of Public Health and Tropical Medicine from Tulane University in New Orleans, Louisiana. In addition, he earned a doctorate in public health at the Uniformed Services University. His medical training includes a residency in general preventive medicine and public health through the National Capital Consortium in Bethesda, Maryland, a certificate in tropical medicine (American Society of Travel Medicine and Hygiene), and an advanced vaccinology course (Fondation Mérieux, Annecy, France). Active in research, Dr. Riddle has served as a principal investigator or co-investigator for numerous basic science, translational, and clinical studies in areas such as vaccines, drug development, and epidemiology of acute enteric infections and their chronic consequences. His work has been published in Nature Microbiology, Lancet, Journal of Infectious Diseases, Clinical Infectious Diseases, Vaccine, American Journal of Gastroenterology, Gastroenterology, Gut and Digestive Diseases and Sciences, among others. Dr. Riddle has been invited to present his work at meetings, grand rounds, and advisory boards in the United States and internationally. He is diplomate of the American Board of Preventive Medicine. Dr. Riddle is also a member of the American College of Gastroenterology, the International Society of Travel Medicine, and serves as faculty and scientific board for the annual Old Herborn University Seminar on host-microbiota interaction for the benefit of human health.

A few of Dr. Riddle's most significant accomplishments include:
1. Defining the epidemiology of post-infectious gastrointestinal consequences through the use of large Department of Defense Medical Encounter databases
2. Advancing the evidence for effectiveness and safety of loperamide-adjuncted single dose antibiotic therapy for traveler's diarrhea
3. Describing the importance of microbial antibodies in the association with the development of post-infectious irritable bowel syndrome
4. Developing models to evaluate the economic value of vaccines for use to prevent traveler's diarrhea
5. Discovering biomarkers that predict the Crohn's disease phenotype well before clinical diagnosis

SPEAKER DISCLOSURES

Grants/Research Support:  Janssen, Sanofi Pasteur

Consultant/Advisory Board Membership/Honorarium Recipient:  American College of Gastroenterology, International Society of Travel Medicine, Focus Medical Communications, Provention Bio, Inc.

Editorial Board Involvement:  BMC Gastroenterology, Tropical Diseases Travel Medicine and Vaccines,
PLOS One

Gary D. Wu, MD
Professor of Medicine
Ferdinand G. Weisbrod Chair in Gastroenterology
Co-Director, PennCHOP Microbiome Program
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Gary D. Wu, MD, is the Ferdinand G. Weisbrod professor in gastroenterology at the Perelman School of Medicine at the University of Pennsylvania where he is the associate chief of research in the Division of Gastroenterology, associate director of the NIH Center for Molecular Studies in Digestive and Liver Disease, and co-director of the PennCHOP Microbiome Program. He was the inaugural director and chair of the Scientific Advisory Board for the American Gastroenterological Association Center for Gut Microbiome Research and Education and is an elected member of both the ASCI and AAP. Research programs in the Wu laboratory focus on the mutualistic interactions between the gut microbiota and its host with particular emphasis on metabolism including nitrogen balance, intestinal oxygen regulation, and epithelial intermediary metabolism. This includes studies on the effect of diet on the gut microbiome and its relationship to therapeutic responses associated with the use of defined formula diets in the treatment of Crohn's disease.

SPEAKER DISCLOSURES

Grants/Research Support:  Intercept Pharmaceuticals, Nestle, Seres Therapeutics and Takeda

Advisory Board Membership:  Chr. Hansen, BioCodex, Janssen and Nestle

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.